IN8bio, Inc. Common Stock (INAB)
IN8bio, Inc. (INAB) is a clinical-stage biotechnology company focused on developing innovative cell therapies for the treatment of resistant and hard-to-treat cancers. The company leverages its proprietary gamma delta T cell platform to engineer and enhance immune responses against tumors, aiming to improve patient outcomes through its advanced immunotherapy approaches.
Company News
IN8bio's gamma-delta T cell therapy INB-200 has demonstrated a significant clinical milestone, with a patient with a grade 4, IDH-mutant glioma remaining in remission and progression-free for 4 years after treatment. This outcome highlights the potential of INB-200 in treating this aggressive and deadly cancer.
Shares of PriceSmart, Inc. (NASDAQ: PSMT) rose sharply in today’s pre-market trading as the company posted better-than-expected earnings for its second quarter. The company reported quarterly earnings of $1.31 per share, beating market estimates of $1.25 per share. PriceSmart’s quarterly sales came in at $1.29 billion versus expectations of ...
Get the latest financial updates and insights with Wall Street Breakfast's daily podcast available on Seeking Alpha, iTunes, and Spotify.
IN8bio, Inc. (INAB) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Penny stocks under $5 to watch this week. The post Best Penny Stocks To Buy Today? 4 To Watch Under $5 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.